Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adriamycin cardiomyopathy--risk factors

R A Minow, R S Benjamin, E T Lee

    Cancer
    |April 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) morphologic, qualitative, semiquantitative, and radiomics features predicting undifferentiated pleomorphic sarcoma (UPS) treatment response.

    Scientific reports·2024
    Same author

    Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.

    Scientific reports·2017
    Same author

    Plasminogen activator inhibitor-1 is associated with leukocyte telomere length in American Indians: findings from the Strong Heart Family Study.

    Journal of thrombosis and haemostasis : JTH·2017
    Same author

    Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

    Annals of oncology : official journal of the European Society for Medical Oncology·2014
    Same author

    Serum uric acid does not predict incident metabolic syndrome in a population with high prevalence of obesity.

    Nutrition, metabolism, and cardiovascular diseases : NMCD·2014
    Same author

    Cardiometabolic risk in overweight subjects with or without relative fat-free mass deficiency: the Strong Heart Study.

    Nutrition, metabolism, and cardiovascular diseases : NMCD·2013
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    Same journal

    Most older patients with advanced cancer prioritize QOL over extending survival: A secondary analysis of the GAP70+ trial found that among adults aged 70 and older with advanced, noncurable cancer, nearly three-quarters prioritized maintaining QOL.

    Cancer·2026
    Same journal

    Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

    Cancer·2026
    See all related articles

    Adriamycin cardiomyopathy risk increases with a 30% QRS voltage decrease. Concurrent therapies and hypertension potentiate toxicity, impacting Adriamycin treatment safety.

    Area of Science:

    • Cardiology
    • Oncology
    • Pharmacology

    Background:

    • Adriamycin (doxorubicin) is a widely used chemotherapy agent.
    • Adriamycin-induced cardiomyopathy (AIC) is a serious dose-limiting toxicity.
    • Identifying risk factors for AIC is crucial for patient safety.

    Purpose of the Study:

    • To analyze factors associated with Adriamycin cardiomyopathy.
    • To identify predictors of Adriamycin-induced congestive heart failure.

    Main Methods:

    • Retrospective analysis of 53 patients treated with Adriamycin.
    • Comparison of patients who developed congestive heart failure (n=17) versus those who did not (n=36).
    • Assessment of limb-lead QRS voltage changes and concurrent treatments.

    Related Experiment Videos

    Main Results:

    • A >=30% decrease in limb-lead QRS voltage was significantly associated with increased cardiomyopathy risk.
    • Concurrent cyclophosphamide and mediastinal radiotherapy lowered the cumulative Adriamycin dose for cardiotoxicity.
    • Uncontrolled hypertension potentiated AIC development at lower doses.
    • Congestive heart failure was more likely fatal if occurring soon after the last Adriamycin dose.

    Conclusions:

    • Limb-lead QRS voltage decrease is a key indicator for Adriamycin cardiotoxicity.
    • Combination therapies and hypertension necessitate careful monitoring during Adriamycin treatment.
    • Findings can guide safer Adriamycin administration protocols.